| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiomyopathy, Hypertrophic | 311 | 2025 | 750 | 60.060 |
Why?
|
| Death, Sudden, Cardiac | 166 | 2024 | 354 | 35.090 |
Why?
|
| Defibrillators, Implantable | 73 | 2024 | 258 | 19.240 |
Why?
|
| Athletes | 50 | 2024 | 97 | 16.950 |
Why?
|
| Sports | 46 | 2024 | 92 | 10.730 |
Why?
|
| Ventricular Outflow Obstruction | 43 | 2025 | 114 | 9.710 |
Why?
|
| Cardiology | 24 | 2019 | 165 | 8.830 |
Why?
|
| Tachycardia, Ventricular | 31 | 2023 | 118 | 8.290 |
Why?
|
| Heart Failure | 45 | 2024 | 867 | 6.890 |
Why?
|
| Electrocardiography | 73 | 2024 | 524 | 6.830 |
Why?
|
| Humans | 456 | 2025 | 59495 | 6.400 |
Why?
|
| Takotsubo Cardiomyopathy | 18 | 2021 | 64 | 6.330 |
Why?
|
| Hypertrophy, Left Ventricular | 33 | 2023 | 122 | 6.140 |
Why?
|
| Risk Assessment | 66 | 2024 | 1914 | 5.810 |
Why?
|
| Atrial Fibrillation | 26 | 2024 | 798 | 5.730 |
Why?
|
| Cardiac Surgical Procedures | 26 | 2022 | 249 | 5.680 |
Why?
|
| American Heart Association | 23 | 2019 | 128 | 5.660 |
Why?
|
| Electric Countershock | 22 | 2024 | 98 | 5.600 |
Why?
|
| Ventricular Fibrillation | 31 | 2023 | 99 | 5.550 |
Why?
|
| Heart Septum | 25 | 2022 | 55 | 5.400 |
Why?
|
| Commotio Cordis | 12 | 2023 | 12 | 5.020 |
Why?
|
| Heart Ventricles | 35 | 2022 | 251 | 4.750 |
Why?
|
| Male | 247 | 2025 | 27562 | 4.580 |
Why?
|
| Heart Arrest | 14 | 2023 | 158 | 4.390 |
Why?
|
| Echocardiography | 50 | 2021 | 459 | 4.280 |
Why?
|
| Adult | 186 | 2025 | 15783 | 4.250 |
Why?
|
| Cardiovascular Diseases | 21 | 2023 | 827 | 4.200 |
Why?
|
| Cardiovascular Abnormalities | 14 | 2015 | 32 | 4.090 |
Why?
|
| Risk Factors | 91 | 2024 | 5015 | 4.070 |
Why?
|
| Advisory Committees | 14 | 2015 | 107 | 3.860 |
Why?
|
| Death, Sudden | 15 | 2023 | 27 | 3.820 |
Why?
|
| Ventricular Septum | 11 | 2022 | 30 | 3.820 |
Why?
|
| Female | 215 | 2025 | 30908 | 3.800 |
Why?
|
| Adolescent | 108 | 2024 | 5930 | 3.710 |
Why?
|
| Registries | 26 | 2024 | 803 | 3.660 |
Why?
|
| Mass Screening | 20 | 2018 | 647 | 3.520 |
Why?
|
| Cardiomyopathy, Hypertrophic, Familial | 12 | 2023 | 28 | 3.510 |
Why?
|
| Middle Aged | 146 | 2025 | 16275 | 3.330 |
Why?
|
| Young Adult | 71 | 2024 | 4329 | 3.240 |
Why?
|
| Catheter Ablation | 13 | 2023 | 138 | 3.190 |
Why?
|
| Prognosis | 47 | 2024 | 1572 | 3.100 |
Why?
|
| Magnetic Resonance Imaging | 32 | 2023 | 2040 | 3.080 |
Why?
|
| Genetic Predisposition to Disease | 19 | 2024 | 674 | 3.070 |
Why?
|
| Magnetic Resonance Imaging, Cine | 25 | 2024 | 108 | 3.040 |
Why?
|
| Ventricular Function, Left | 20 | 2025 | 263 | 3.010 |
Why?
|
| Sarcomeres | 14 | 2024 | 51 | 2.920 |
Why?
|
| Cardiomyopathies | 16 | 2022 | 119 | 2.910 |
Why?
|
| Child | 69 | 2022 | 4304 | 2.880 |
Why?
|
| Follow-Up Studies | 57 | 2025 | 2329 | 2.800 |
Why?
|
| Cardiopulmonary Resuscitation | 10 | 2023 | 85 | 2.790 |
Why?
|
| Myocardium | 17 | 2020 | 262 | 2.600 |
Why?
|
| Wounds, Nonpenetrating | 16 | 2023 | 106 | 2.510 |
Why?
|
| Heart Aneurysm | 8 | 2021 | 23 | 2.460 |
Why?
|
| Running | 6 | 2018 | 80 | 2.460 |
Why?
|
| Phenotype | 33 | 2024 | 1157 | 2.460 |
Why?
|
| Heart Transplantation | 12 | 2024 | 159 | 2.430 |
Why?
|
| Athletic Injuries | 16 | 2019 | 72 | 2.390 |
Why?
|
| Mutation | 26 | 2024 | 2429 | 2.370 |
Why?
|
| Arrhythmias, Cardiac | 21 | 2024 | 142 | 2.370 |
Why?
|
| Treatment Outcome | 57 | 2025 | 5183 | 2.290 |
Why?
|
| Primary Prevention | 11 | 2021 | 137 | 2.280 |
Why?
|
| Myocarditis | 7 | 2020 | 61 | 2.250 |
Why?
|
| Aged | 92 | 2025 | 13339 | 2.220 |
Why?
|
| United States | 67 | 2024 | 7511 | 2.140 |
Why?
|
| Thoracic Injuries | 15 | 2019 | 48 | 2.110 |
Why?
|
| Gadolinium | 12 | 2021 | 102 | 1.980 |
Why?
|
| Disease Management | 8 | 2020 | 220 | 1.950 |
Why?
|
| Echocardiography, Doppler | 15 | 2017 | 131 | 1.890 |
Why?
|
| Sickle Cell Trait | 4 | 2015 | 7 | 1.850 |
Why?
|
| Prevalence | 26 | 2023 | 1281 | 1.830 |
Why?
|
| Students | 7 | 2014 | 207 | 1.790 |
Why?
|
| Arrhythmogenic Right Ventricular Dysplasia | 6 | 2016 | 13 | 1.750 |
Why?
|
| Vascular Diseases | 2 | 2024 | 69 | 1.710 |
Why?
|
| Longevity | 4 | 2018 | 111 | 1.680 |
Why?
|
| Cause of Death | 14 | 2017 | 200 | 1.650 |
Why?
|
| Ventricular Dysfunction, Left | 12 | 2020 | 160 | 1.650 |
Why?
|
| Practice Guidelines as Topic | 20 | 2019 | 703 | 1.640 |
Why?
|
| Contrast Media | 14 | 2021 | 410 | 1.640 |
Why?
|
| Quality of Life | 10 | 2024 | 1116 | 1.640 |
Why?
|
| Baseball | 8 | 2021 | 11 | 1.580 |
Why?
|
| Aged, 80 and over | 38 | 2020 | 5089 | 1.580 |
Why?
|
| Heart Defects, Congenital | 6 | 2018 | 96 | 1.560 |
Why?
|
| Ablation Techniques | 5 | 2020 | 22 | 1.540 |
Why?
|
| Survival Rate | 22 | 2024 | 791 | 1.520 |
Why?
|
| Ventricular Remodeling | 8 | 2020 | 80 | 1.520 |
Why?
|
| Benzylamines | 2 | 2022 | 29 | 1.500 |
Why?
|
| Retrospective Studies | 50 | 2025 | 6008 | 1.500 |
Why?
|
| Incidence | 26 | 2022 | 1237 | 1.500 |
Why?
|
| Anti-Arrhythmia Agents | 11 | 2025 | 93 | 1.470 |
Why?
|
| Disease Progression | 21 | 2024 | 1044 | 1.430 |
Why?
|
| Predictive Value of Tests | 21 | 2024 | 1031 | 1.330 |
Why?
|
| Mitral Valve Prolapse | 3 | 2024 | 11 | 1.310 |
Why?
|
| Cohort Studies | 28 | 2024 | 2442 | 1.310 |
Why?
|
| Survival Analysis | 19 | 2019 | 553 | 1.310 |
Why?
|
| Time Factors | 26 | 2025 | 3579 | 1.290 |
Why?
|
| History, 20th Century | 13 | 2020 | 225 | 1.270 |
Why?
|
| Mitral Valve | 6 | 2020 | 104 | 1.270 |
Why?
|
| Stroke Volume | 16 | 2021 | 318 | 1.260 |
Why?
|
| Prospective Studies | 24 | 2023 | 3101 | 1.230 |
Why?
|
| Heart Conduction System | 4 | 2021 | 49 | 1.230 |
Why?
|
| Heart Diseases | 5 | 2019 | 204 | 1.200 |
Why?
|
| Acute Coronary Syndrome | 3 | 2019 | 258 | 1.150 |
Why?
|
| Patient Selection | 11 | 2018 | 446 | 1.140 |
Why?
|
| Minnesota | 14 | 2016 | 37 | 1.130 |
Why?
|
| Diseases in Twins | 3 | 2020 | 54 | 1.130 |
Why?
|
| Adrenergic beta-Antagonists | 10 | 2020 | 149 | 1.080 |
Why?
|
| Marfan Syndrome | 5 | 2015 | 17 | 1.070 |
Why?
|
| Aortic Diseases | 3 | 2015 | 67 | 1.070 |
Why?
|
| Age Factors | 19 | 2019 | 1518 | 1.070 |
Why?
|
| Football | 4 | 2023 | 16 | 1.070 |
Why?
|
| Physicians | 3 | 2020 | 436 | 1.060 |
Why?
|
| Ethanol | 6 | 2017 | 307 | 1.050 |
Why?
|
| Stroke | 7 | 2024 | 1138 | 1.040 |
Why?
|
| Terminology as Topic | 6 | 2018 | 137 | 1.030 |
Why?
|
| Severity of Illness Index | 26 | 2019 | 1449 | 1.020 |
Why?
|
| Sports Medicine | 5 | 2008 | 22 | 1.020 |
Why?
|
| Amyloid Neuropathies, Familial | 2 | 2022 | 17 | 0.960 |
Why?
|
| Cat Diseases | 2 | 2015 | 16 | 0.950 |
Why?
|
| Diagnosis, Differential | 17 | 2019 | 900 | 0.940 |
Why?
|
| Public Policy | 2 | 2015 | 41 | 0.940 |
Why?
|
| Swimming | 2 | 2017 | 21 | 0.930 |
Why?
|
| Amyloidosis | 2 | 2022 | 58 | 0.930 |
Why?
|
| Uracil | 2 | 2022 | 30 | 0.920 |
Why?
|
| Precision Medicine | 2 | 2022 | 103 | 0.920 |
Why?
|
| Bicycling | 2 | 2017 | 24 | 0.910 |
Why?
|
| Vasoconstrictor Agents | 2 | 2014 | 64 | 0.910 |
Why?
|
| Carrier Proteins | 10 | 2020 | 710 | 0.910 |
Why?
|
| Hypertension, Pulmonary | 2 | 2022 | 78 | 0.900 |
Why?
|
| Soccer | 2 | 2022 | 13 | 0.890 |
Why?
|
| History, 21st Century | 8 | 2020 | 161 | 0.890 |
Why?
|
| Genetic Testing | 7 | 2024 | 132 | 0.880 |
Why?
|
| Exercise Test | 9 | 2018 | 234 | 0.880 |
Why?
|
| Myocardial Infarction | 7 | 2018 | 864 | 0.870 |
Why?
|
| Sex Factors | 14 | 2019 | 960 | 0.870 |
Why?
|
| Academic Medical Centers | 2 | 2015 | 314 | 0.860 |
Why?
|
| Ultrasonography | 15 | 2015 | 452 | 0.850 |
Why?
|
| Hospitals, Special | 2 | 2015 | 8 | 0.830 |
Why?
|
| Syncope | 6 | 2020 | 42 | 0.820 |
Why?
|
| Genotype | 13 | 2024 | 642 | 0.820 |
Why?
|
| Mandatory Testing | 2 | 2012 | 2 | 0.800 |
Why?
|
| Congresses as Topic | 3 | 2018 | 72 | 0.790 |
Why?
|
| Societies, Medical | 9 | 2015 | 330 | 0.790 |
Why?
|
| Heart Atria | 5 | 2015 | 138 | 0.790 |
Why?
|
| Cardiomyopathy, Dilated | 3 | 2016 | 33 | 0.780 |
Why?
|
| Glycogen Storage Disease | 2 | 2020 | 3 | 0.770 |
Why?
|
| Cardiovascular Agents | 2 | 2022 | 100 | 0.770 |
Why?
|
| Myosin Heavy Chains | 6 | 2017 | 40 | 0.770 |
Why?
|
| Embolization, Therapeutic | 2 | 2015 | 307 | 0.760 |
Why?
|
| Italy | 14 | 2014 | 62 | 0.760 |
Why?
|
| Fibrosis | 11 | 2023 | 151 | 0.760 |
Why?
|
| Europe | 9 | 2018 | 183 | 0.750 |
Why?
|
| Defibrillators | 9 | 2012 | 16 | 0.750 |
Why?
|
| Fabry Disease | 3 | 2017 | 8 | 0.740 |
Why?
|
| Prodromal Symptoms | 1 | 2020 | 12 | 0.730 |
Why?
|
| Heart Injuries | 6 | 2008 | 18 | 0.720 |
Why?
|
| DNA | 5 | 2014 | 794 | 0.720 |
Why?
|
| Pedigree | 11 | 2020 | 190 | 0.710 |
Why?
|
| Child, Preschool | 16 | 2017 | 1839 | 0.710 |
Why?
|
| Twins, Monozygotic | 3 | 2020 | 69 | 0.700 |
Why?
|
| Judgment | 1 | 2020 | 30 | 0.700 |
Why?
|
| Universities | 3 | 2024 | 152 | 0.700 |
Why?
|
| Coronary Artery Disease | 4 | 2016 | 277 | 0.690 |
Why?
|
| Echocardiography, Transesophageal | 4 | 2017 | 94 | 0.690 |
Why?
|
| Coronary Angiography | 5 | 2019 | 172 | 0.680 |
Why?
|
| Athletic Performance | 2 | 2010 | 7 | 0.680 |
Why?
|
| Circadian Rhythm | 4 | 2013 | 370 | 0.680 |
Why?
|
| Disopyramide | 3 | 2025 | 10 | 0.670 |
Why?
|
| Consensus | 3 | 2019 | 194 | 0.660 |
Why?
|
| Coronary Vessel Anomalies | 3 | 2016 | 15 | 0.660 |
Why?
|
| Genetic Heterogeneity | 1 | 2019 | 23 | 0.650 |
Why?
|
| Heart Rate | 8 | 2017 | 306 | 0.650 |
Why?
|
| Competitive Behavior | 2 | 2009 | 8 | 0.650 |
Why?
|
| Global Health | 6 | 2021 | 163 | 0.650 |
Why?
|
| Thoracic Surgery | 2 | 2017 | 66 | 0.640 |
Why?
|
| Electrocardiography, Ambulatory | 9 | 2017 | 39 | 0.640 |
Why?
|
| Aging | 3 | 2014 | 723 | 0.630 |
Why?
|
| Cardiac Myosins | 3 | 2017 | 22 | 0.630 |
Why?
|
| Proportional Hazards Models | 9 | 2021 | 673 | 0.630 |
Why?
|
| Motor Activity | 4 | 2013 | 343 | 0.620 |
Why?
|
| Stress, Psychological | 4 | 2013 | 443 | 0.600 |
Why?
|
| Referral and Consultation | 2 | 2019 | 409 | 0.600 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 5 | 2017 | 23 | 0.590 |
Why?
|
| Time-to-Treatment | 1 | 2018 | 101 | 0.590 |
Why?
|
| Reproducibility of Results | 10 | 2022 | 1551 | 0.590 |
Why?
|
| Equipment Failure | 5 | 2019 | 65 | 0.590 |
Why?
|
| Tertiary Healthcare | 1 | 2017 | 13 | 0.580 |
Why?
|
| Exercise | 6 | 2014 | 916 | 0.580 |
Why?
|
| Critical Pathways | 1 | 2017 | 32 | 0.570 |
Why?
|
| Diagnostic Imaging | 2 | 2018 | 242 | 0.570 |
Why?
|
| Solvents | 2 | 2014 | 58 | 0.570 |
Why?
|
| Aortic Valve | 4 | 2017 | 168 | 0.560 |
Why?
|
| Cardiac Pacing, Artificial | 3 | 2013 | 34 | 0.560 |
Why?
|
| Cost of Illness | 1 | 2018 | 155 | 0.560 |
Why?
|
| Coronary Aneurysm | 2 | 2008 | 7 | 0.560 |
Why?
|
| Healthcare Disparities | 2 | 2018 | 330 | 0.550 |
Why?
|
| Health Status Disparities | 1 | 2018 | 147 | 0.540 |
Why?
|
| Age Distribution | 7 | 2017 | 261 | 0.530 |
Why?
|
| Heart Valve Diseases | 2 | 2015 | 88 | 0.530 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2016 | 35 | 0.520 |
Why?
|
| Shock, Cardiogenic | 2 | 2021 | 85 | 0.520 |
Why?
|
| Channelopathies | 1 | 2015 | 5 | 0.510 |
Why?
|
| Troponin T | 5 | 2014 | 23 | 0.510 |
Why?
|
| Emergency Medical Services | 4 | 2007 | 249 | 0.500 |
Why?
|
| Private Practice | 1 | 2015 | 10 | 0.500 |
Why?
|
| Hemodynamics | 5 | 2020 | 236 | 0.500 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2015 | 7 | 0.490 |
Why?
|
| Catecholamines | 1 | 2015 | 30 | 0.480 |
Why?
|
| Physical Exertion | 4 | 2018 | 78 | 0.480 |
Why?
|
| Intraoperative Complications | 1 | 2015 | 81 | 0.480 |
Why?
|
| Decision Making | 2 | 2017 | 390 | 0.480 |
Why?
|
| Pheochromocytoma | 1 | 2015 | 27 | 0.480 |
Why?
|
| Alcohols | 1 | 2014 | 13 | 0.480 |
Why?
|
| Heart | 5 | 2022 | 276 | 0.480 |
Why?
|
| Developing Countries | 1 | 2015 | 84 | 0.470 |
Why?
|
| Longitudinal Studies | 5 | 2021 | 1225 | 0.470 |
Why?
|
| Frameshift Mutation | 2 | 2012 | 28 | 0.470 |
Why?
|
| Anticoagulants | 5 | 2024 | 487 | 0.460 |
Why?
|
| Career Choice | 1 | 2015 | 110 | 0.460 |
Why?
|
| Atrial Remodeling | 1 | 2014 | 17 | 0.450 |
Why?
|
| Autopsy | 5 | 2020 | 47 | 0.450 |
Why?
|
| Atrial Function, Left | 1 | 2014 | 31 | 0.450 |
Why?
|
| Cardiomyopathy, Restrictive | 1 | 2013 | 2 | 0.450 |
Why?
|
| Boston | 3 | 2020 | 331 | 0.440 |
Why?
|
| Gadolinium DTPA | 5 | 2017 | 85 | 0.440 |
Why?
|
| Physical Endurance | 2 | 2012 | 48 | 0.440 |
Why?
|
| Recovery of Function | 7 | 2020 | 261 | 0.440 |
Why?
|
| Ventricular Function, Right | 1 | 2013 | 27 | 0.440 |
Why?
|
| Multivariate Analysis | 8 | 2015 | 926 | 0.440 |
Why?
|
| Australia | 4 | 2018 | 94 | 0.430 |
Why?
|
| Anxiety | 2 | 2018 | 395 | 0.430 |
Why?
|
| Protective Devices | 3 | 2008 | 12 | 0.420 |
Why?
|
| Specialties, Surgical | 1 | 2013 | 44 | 0.420 |
Why?
|
| Cardiotonic Agents | 3 | 2018 | 48 | 0.420 |
Why?
|
| Lysosomal-Associated Membrane Protein 2 | 5 | 2021 | 14 | 0.420 |
Why?
|
| Emergency Treatment | 3 | 2007 | 51 | 0.410 |
Why?
|
| Sclerotherapy | 1 | 2012 | 10 | 0.400 |
Why?
|
| Sports Equipment | 3 | 2007 | 5 | 0.400 |
Why?
|
| Lamin Type A | 1 | 2012 | 11 | 0.390 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2016 | 387 | 0.390 |
Why?
|
| Magnetic Resonance Spectroscopy | 3 | 2021 | 293 | 0.390 |
Why?
|
| Case-Control Studies | 8 | 2021 | 1063 | 0.390 |
Why?
|
| Long QT Syndrome | 2 | 2016 | 28 | 0.380 |
Why?
|
| Glycogen Storage Disease Type IIb | 2 | 2021 | 4 | 0.370 |
Why?
|
| Sex Distribution | 4 | 2017 | 254 | 0.370 |
Why?
|
| Troponin C | 1 | 2011 | 2 | 0.370 |
Why?
|
| Age of Onset | 6 | 2020 | 172 | 0.370 |
Why?
|
| Hypothermia, Induced | 1 | 2011 | 42 | 0.370 |
Why?
|
| Clinical Decision-Making | 4 | 2019 | 141 | 0.370 |
Why?
|
| Chi-Square Distribution | 5 | 2013 | 403 | 0.360 |
Why?
|
| Sudden Infant Death | 2 | 2014 | 22 | 0.360 |
Why?
|
| Systole | 7 | 2021 | 109 | 0.360 |
Why?
|
| Biomarkers | 6 | 2019 | 1210 | 0.360 |
Why?
|
| Heart Septal Defects | 1 | 2010 | 2 | 0.350 |
Why?
|
| Racquet Sports | 2 | 2009 | 4 | 0.350 |
Why?
|
| Prosthesis Implantation | 2 | 2007 | 30 | 0.350 |
Why?
|
| Cardiac Imaging Techniques | 2 | 2022 | 16 | 0.350 |
Why?
|
| Donor Selection | 1 | 2009 | 16 | 0.340 |
Why?
|
| Safety | 3 | 2005 | 141 | 0.330 |
Why?
|
| Endocarditis, Bacterial | 1 | 2009 | 30 | 0.330 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2009 | 50 | 0.330 |
Why?
|
| Myocardial Bridging | 1 | 2009 | 1 | 0.330 |
Why?
|
| Incidental Findings | 1 | 2009 | 40 | 0.330 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2015 | 1463 | 0.320 |
Why?
|
| Family | 1 | 2010 | 220 | 0.320 |
Why?
|
| Tissue Donors | 1 | 2009 | 133 | 0.320 |
Why?
|
| Analysis of Variance | 5 | 2014 | 576 | 0.320 |
Why?
|
| Echocardiography, Stress | 3 | 2017 | 13 | 0.320 |
Why?
|
| Positron-Emission Tomography | 1 | 2009 | 172 | 0.320 |
Why?
|
| Papillary Muscles | 4 | 2013 | 14 | 0.310 |
Why?
|
| Animals | 18 | 2021 | 19648 | 0.310 |
Why?
|
| Endomyocardial Fibrosis | 1 | 2008 | 4 | 0.310 |
Why?
|
| Tachycardia, Supraventricular | 2 | 2005 | 9 | 0.310 |
Why?
|
| Cardiomegaly | 4 | 2021 | 28 | 0.310 |
Why?
|
| New Jersey | 2 | 2018 | 26 | 0.300 |
Why?
|
| Military Personnel | 2 | 2014 | 97 | 0.300 |
Why?
|
| DNA Mutational Analysis | 5 | 2014 | 195 | 0.300 |
Why?
|
| Clinical Trials as Topic | 2 | 2008 | 442 | 0.300 |
Why?
|
| Confidence Intervals | 3 | 2013 | 256 | 0.300 |
Why?
|
| Mass Media | 1 | 2008 | 30 | 0.300 |
Why?
|
| Internship and Residency | 1 | 2015 | 723 | 0.290 |
Why?
|
| Infant | 6 | 2011 | 1527 | 0.290 |
Why?
|
| Founder Effect | 2 | 2020 | 11 | 0.290 |
Why?
|
| Morbidity | 2 | 2020 | 109 | 0.290 |
Why?
|
| Hospital Mortality | 3 | 2019 | 846 | 0.290 |
Why?
|
| Patient Rights | 1 | 2007 | 15 | 0.290 |
Why?
|
| Recreation | 1 | 2007 | 22 | 0.290 |
Why?
|
| Cross-Sectional Studies | 7 | 2020 | 2468 | 0.290 |
Why?
|
| Spermatozoa | 1 | 2009 | 251 | 0.280 |
Why?
|
| Medical Informatics | 1 | 2008 | 68 | 0.280 |
Why?
|
| Myocardial Contraction | 3 | 2014 | 83 | 0.280 |
Why?
|
| Ventricular Function | 3 | 2017 | 21 | 0.280 |
Why?
|
| Tachycardia | 2 | 2008 | 27 | 0.280 |
Why?
|
| Drug Industry | 1 | 2007 | 40 | 0.280 |
Why?
|
| Silicon Dioxide | 1 | 2007 | 59 | 0.280 |
Why?
|
| Denmark | 3 | 2016 | 22 | 0.270 |
Why?
|
| Thrombolytic Therapy | 1 | 2008 | 181 | 0.270 |
Why?
|
| Chest Pain | 3 | 2020 | 85 | 0.260 |
Why?
|
| Probability | 5 | 2007 | 172 | 0.260 |
Why?
|
| Canada | 3 | 2017 | 145 | 0.260 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2005 | 24 | 0.250 |
Why?
|
| Device Approval | 1 | 2005 | 14 | 0.250 |
Why?
|
| Troponin | 2 | 2019 | 37 | 0.250 |
Why?
|
| Sensitivity and Specificity | 5 | 2014 | 1095 | 0.250 |
Why?
|
| Public Health | 1 | 2007 | 180 | 0.250 |
Why?
|
| Potassium Channels, Voltage-Gated | 1 | 2005 | 31 | 0.250 |
Why?
|
| Stress, Physiological | 1 | 2007 | 186 | 0.240 |
Why?
|
| Bradycardia | 1 | 2005 | 34 | 0.240 |
Why?
|
| Cats | 2 | 2015 | 81 | 0.240 |
Why?
|
| Mortality | 2 | 2015 | 159 | 0.230 |
Why?
|
| Statistics, Nonparametric | 3 | 2017 | 208 | 0.230 |
Why?
|
| Indians, North American | 1 | 2004 | 26 | 0.230 |
Why?
|
| Echocardiography, Doppler, Pulsed | 2 | 2014 | 6 | 0.230 |
Why?
|
| Hospitalization | 1 | 2011 | 1282 | 0.230 |
Why?
|
| India | 2 | 2015 | 157 | 0.230 |
Why?
|
| Patient Education as Topic | 1 | 2008 | 446 | 0.230 |
Why?
|
| Accidents, Aviation | 1 | 2004 | 2 | 0.230 |
Why?
|
| Aerospace Medicine | 1 | 2004 | 6 | 0.230 |
Why?
|
| Internet | 1 | 2008 | 458 | 0.230 |
Why?
|
| Physical Education and Training | 1 | 2004 | 31 | 0.230 |
Why?
|
| Species Specificity | 2 | 2015 | 336 | 0.230 |
Why?
|
| Recurrence | 3 | 2017 | 578 | 0.220 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2004 | 52 | 0.220 |
Why?
|
| Heterozygote | 3 | 2020 | 168 | 0.220 |
Why?
|
| Electrodes | 2 | 2014 | 36 | 0.220 |
Why?
|
| Cross-Cultural Comparison | 1 | 2004 | 45 | 0.220 |
Why?
|
| Atrial Appendage | 1 | 2024 | 28 | 0.220 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2007 | 668 | 0.220 |
Why?
|
| Mitral Valve Insufficiency | 3 | 2021 | 75 | 0.220 |
Why?
|
| Hockey | 1 | 2003 | 4 | 0.220 |
Why?
|
| Carotid Artery Injuries | 1 | 2003 | 12 | 0.220 |
Why?
|
| Health Planning Guidelines | 5 | 2007 | 31 | 0.220 |
Why?
|
| Life Expectancy | 1 | 2003 | 34 | 0.220 |
Why?
|
| Image Enhancement | 3 | 2015 | 190 | 0.220 |
Why?
|
| Neck Injuries | 1 | 2003 | 19 | 0.220 |
Why?
|
| Vertebral Artery | 1 | 2003 | 27 | 0.220 |
Why?
|
| Massachusetts | 3 | 2020 | 2086 | 0.220 |
Why?
|
| Swine | 10 | 2018 | 344 | 0.210 |
Why?
|
| Carnitine O-Palmitoyltransferase | 1 | 2002 | 5 | 0.210 |
Why?
|
| Tertiary Care Centers | 2 | 2020 | 102 | 0.210 |
Why?
|
| Logistic Models | 3 | 2012 | 1252 | 0.210 |
Why?
|
| Reference Values | 2 | 2016 | 321 | 0.210 |
Why?
|
| United Kingdom | 2 | 2019 | 69 | 0.210 |
Why?
|
| Vascular Remodeling | 1 | 2022 | 23 | 0.210 |
Why?
|
| Mutation, Missense | 3 | 2017 | 179 | 0.200 |
Why?
|
| Cardiovascular Deconditioning | 3 | 2011 | 3 | 0.200 |
Why?
|
| Cardiac Resynchronization Therapy | 2 | 2020 | 15 | 0.200 |
Why?
|
| Fatal Outcome | 3 | 2007 | 113 | 0.200 |
Why?
|
| Obesity | 2 | 2025 | 1186 | 0.200 |
Why?
|
| Guideline Adherence | 2 | 2019 | 296 | 0.200 |
Why?
|
| Spouses | 1 | 2002 | 38 | 0.200 |
Why?
|
| Darkness | 1 | 2021 | 22 | 0.190 |
Why?
|
| Homicide | 1 | 2002 | 25 | 0.190 |
Why?
|
| Demography | 1 | 2022 | 178 | 0.190 |
Why?
|
| Disease Models, Animal | 8 | 2018 | 2069 | 0.190 |
Why?
|
| Magnetic Resonance Angiography | 3 | 2014 | 180 | 0.190 |
Why?
|
| Dyspnea | 2 | 2018 | 108 | 0.190 |
Why?
|
| Return to Sport | 1 | 2021 | 10 | 0.190 |
Why?
|
| AMP-Activated Protein Kinases | 2 | 2020 | 64 | 0.190 |
Why?
|
| Atrioventricular Node | 1 | 2020 | 9 | 0.180 |
Why?
|
| Multi-Institutional Systems | 1 | 2020 | 5 | 0.180 |
Why?
|
| alpha-Galactosidase | 2 | 2017 | 8 | 0.180 |
Why?
|
| Publication Bias | 1 | 2020 | 21 | 0.180 |
Why?
|
| Comorbidity | 6 | 2021 | 1090 | 0.180 |
Why?
|
| Hospitals, Community | 2 | 2015 | 71 | 0.180 |
Why?
|
| Databases, Factual | 3 | 2017 | 838 | 0.180 |
Why?
|
| Kidney Diseases | 2 | 2019 | 159 | 0.180 |
Why?
|
| Subcutaneous Tissue | 1 | 2020 | 14 | 0.180 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 1 | 2020 | 7 | 0.180 |
Why?
|
| Adaptation, Physiological | 4 | 2012 | 117 | 0.170 |
Why?
|
| Biological Variation, Population | 1 | 2019 | 9 | 0.170 |
Why?
|
| Calcium Channel Blockers | 1 | 2020 | 56 | 0.170 |
Why?
|
| Models, Animal | 2 | 2019 | 221 | 0.170 |
Why?
|
| Lymphocytes | 1 | 2020 | 194 | 0.170 |
Why?
|
| Virus Diseases | 1 | 2020 | 110 | 0.170 |
Why?
|
| Genomics | 1 | 2022 | 314 | 0.170 |
Why?
|
| Gene Regulatory Networks | 1 | 2021 | 139 | 0.170 |
Why?
|
| Physician-Patient Relations | 2 | 2017 | 388 | 0.160 |
Why?
|
| Community Health Services | 1 | 2020 | 128 | 0.160 |
Why?
|
| Infant, Newborn | 2 | 2014 | 1311 | 0.160 |
Why?
|
| Genetic Counseling | 2 | 2012 | 21 | 0.160 |
Why?
|
| Exercise Tolerance | 2 | 2017 | 70 | 0.160 |
Why?
|
| Diastole | 3 | 2016 | 89 | 0.160 |
Why?
|
| Iceland | 3 | 2020 | 8 | 0.160 |
Why?
|
| Ventricular Premature Complexes | 3 | 2008 | 21 | 0.160 |
Why?
|
| Survivors | 3 | 2008 | 148 | 0.160 |
Why?
|
| Models, Theoretical | 1 | 2020 | 258 | 0.160 |
Why?
|
| Secondary Prevention | 1 | 2019 | 153 | 0.150 |
Why?
|
| Gene Expression Regulation | 1 | 2005 | 1538 | 0.150 |
Why?
|
| Cardiac Catheterization | 3 | 2024 | 250 | 0.150 |
Why?
|
| Postoperative Period | 3 | 2023 | 125 | 0.150 |
Why?
|
| Spironolactone | 1 | 2018 | 9 | 0.150 |
Why?
|
| Health Status | 2 | 2018 | 449 | 0.150 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2018 | 11 | 0.150 |
Why?
|
| Waiting Lists | 1 | 2018 | 48 | 0.150 |
Why?
|
| Sotalol | 1 | 2017 | 7 | 0.150 |
Why?
|
| Prosthesis Failure | 1 | 2018 | 70 | 0.150 |
Why?
|
| Enzyme Replacement Therapy | 1 | 2017 | 15 | 0.150 |
Why?
|
| Amiodarone | 1 | 2017 | 21 | 0.150 |
Why?
|
| Genetic Variation | 2 | 2018 | 366 | 0.140 |
Why?
|
| Asymptomatic Diseases | 1 | 2017 | 44 | 0.140 |
Why?
|
| Medical History Taking | 2 | 2007 | 58 | 0.140 |
Why?
|
| Accidents, Traffic | 2 | 2016 | 150 | 0.140 |
Why?
|
| Health Services Needs and Demand | 1 | 2018 | 214 | 0.140 |
Why?
|
| Action Potentials | 1 | 2017 | 103 | 0.140 |
Why?
|
| Physical Examination | 2 | 2007 | 103 | 0.140 |
Why?
|
| Injury Severity Score | 2 | 2008 | 104 | 0.130 |
Why?
|
| Protective Clothing | 2 | 2010 | 29 | 0.130 |
Why?
|
| Pulmonary Artery | 1 | 2017 | 90 | 0.130 |
Why?
|
| Postoperative Complications | 2 | 2023 | 1134 | 0.130 |
Why?
|
| Wolff-Parkinson-White Syndrome | 1 | 2016 | 5 | 0.130 |
Why?
|
| Informed Consent | 2 | 2007 | 133 | 0.130 |
Why?
|
| Rats | 1 | 2019 | 1912 | 0.130 |
Why?
|
| Thoracic Wall | 3 | 2006 | 16 | 0.130 |
Why?
|
| Needs Assessment | 1 | 2017 | 188 | 0.130 |
Why?
|
| Syndrome | 2 | 2007 | 173 | 0.130 |
Why?
|
| Genetic Therapy | 2 | 2018 | 735 | 0.130 |
Why?
|
| Heart-Assist Devices | 1 | 2018 | 126 | 0.130 |
Why?
|
| Eligibility Determination | 1 | 2015 | 34 | 0.130 |
Why?
|
| Evidence-Based Medicine | 2 | 2015 | 452 | 0.130 |
Why?
|
| Ventricular Dysfunction | 2 | 2017 | 10 | 0.130 |
Why?
|
| Radiography | 2 | 2015 | 506 | 0.120 |
Why?
|
| China | 2 | 2007 | 141 | 0.120 |
Why?
|
| Mental Health | 1 | 2018 | 348 | 0.120 |
Why?
|
| Cost-Benefit Analysis | 2 | 2014 | 299 | 0.120 |
Why?
|
| Ethics, Medical | 1 | 2015 | 38 | 0.120 |
Why?
|
| Israel | 1 | 2014 | 18 | 0.120 |
Why?
|
| Thromboembolism | 1 | 2015 | 70 | 0.120 |
Why?
|
| Cicatrix | 2 | 2017 | 58 | 0.110 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 1 | 2014 | 45 | 0.110 |
Why?
|
| Equipment Design | 3 | 2020 | 317 | 0.110 |
Why?
|
| Guidelines as Topic | 2 | 2005 | 158 | 0.110 |
Why?
|
| Forecasting | 1 | 2014 | 221 | 0.110 |
Why?
|
| Nuclear Family | 1 | 2013 | 19 | 0.110 |
Why?
|
| Regression Analysis | 2 | 2005 | 484 | 0.110 |
Why?
|
| Coronary Artery Bypass | 2 | 2022 | 274 | 0.110 |
Why?
|
| Ventricular Pressure | 2 | 2010 | 30 | 0.110 |
Why?
|
| Feasibility Studies | 1 | 2015 | 524 | 0.100 |
Why?
|
| Scalp | 1 | 2013 | 29 | 0.100 |
Why?
|
| Health Surveys | 2 | 2004 | 306 | 0.100 |
Why?
|
| Genetic Privacy | 1 | 2012 | 4 | 0.100 |
Why?
|
| Bisoprolol | 1 | 2012 | 2 | 0.100 |
Why?
|
| Nadolol | 1 | 2012 | 4 | 0.100 |
Why?
|
| Monitoring, Physiologic | 1 | 2013 | 150 | 0.100 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2012 | 113 | 0.090 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2013 | 427 | 0.090 |
Why?
|
| Coronary Care Units | 1 | 2011 | 4 | 0.090 |
Why?
|
| Surgicenters | 1 | 2011 | 6 | 0.090 |
Why?
|
| Algorithms | 2 | 2014 | 990 | 0.090 |
Why?
|
| Protein C | 1 | 2010 | 30 | 0.090 |
Why?
|
| Membrane Proteins | 1 | 2016 | 842 | 0.090 |
Why?
|
| Anniversaries and Special Events | 1 | 2010 | 14 | 0.090 |
Why?
|
| Quality Improvement | 1 | 2015 | 425 | 0.090 |
Why?
|
| Delivery of Health Care | 1 | 2014 | 421 | 0.090 |
Why?
|
| Mothers | 1 | 2013 | 261 | 0.090 |
Why?
|
| Posture | 1 | 2010 | 127 | 0.090 |
Why?
|
| Insemination, Artificial, Heterologous | 1 | 2009 | 1 | 0.090 |
Why?
|
| Sperm Banks | 1 | 2009 | 2 | 0.090 |
Why?
|
| Mice | 2 | 2021 | 10267 | 0.080 |
Why?
|
| Heart Massage | 1 | 2009 | 3 | 0.080 |
Why?
|
| Diagnostic Errors | 1 | 2010 | 98 | 0.080 |
Why?
|
| ROC Curve | 2 | 2014 | 259 | 0.080 |
Why?
|
| Troponin I | 2 | 2009 | 32 | 0.080 |
Why?
|
| Consensus Development Conferences, NIH as Topic | 1 | 2008 | 1 | 0.080 |
Why?
|
| Receptors, Adrenergic, beta-1 | 1 | 2008 | 7 | 0.080 |
Why?
|
| Foundations | 1 | 2008 | 8 | 0.080 |
Why?
|
| Myocardial Ischemia | 1 | 2009 | 109 | 0.080 |
Why?
|
| Receptors, Adrenergic, alpha-2 | 1 | 2008 | 19 | 0.080 |
Why?
|
| Physical Stimulation | 1 | 2008 | 29 | 0.080 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2008 | 10 | 0.080 |
Why?
|
| Marketing | 1 | 2008 | 18 | 0.080 |
Why?
|
| Clinical Competence | 1 | 2013 | 678 | 0.080 |
Why?
|
| Atenolol | 1 | 2007 | 9 | 0.070 |
Why?
|
| Myocytes, Cardiac | 1 | 2008 | 86 | 0.070 |
Why?
|
| Science | 1 | 2008 | 34 | 0.070 |
Why?
|
| Polymorphism, Genetic | 1 | 2008 | 197 | 0.070 |
Why?
|
| Coronary Disease | 1 | 2009 | 250 | 0.070 |
Why?
|
| Bathing Beaches | 1 | 2007 | 6 | 0.070 |
Why?
|
| Ethics, Clinical | 1 | 2007 | 3 | 0.070 |
Why?
|
| Equipment and Supplies | 1 | 2007 | 17 | 0.070 |
Why?
|
| Lightning | 1 | 2007 | 1 | 0.070 |
Why?
|
| Heat Stroke | 1 | 2007 | 3 | 0.070 |
Why?
|
| Volunteers | 1 | 2007 | 17 | 0.070 |
Why?
|
| Conflict of Interest | 1 | 2007 | 35 | 0.070 |
Why?
|
| Cardiac Output, Low | 1 | 2006 | 10 | 0.070 |
Why?
|
| Health Planning | 1 | 2007 | 30 | 0.070 |
Why?
|
| Valsalva Maneuver | 1 | 2006 | 12 | 0.070 |
Why?
|
| Autonomic Nervous System | 1 | 2006 | 30 | 0.070 |
Why?
|
| Acute Disease | 2 | 2007 | 659 | 0.070 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2007 | 167 | 0.070 |
Why?
|
| North America | 1 | 2006 | 114 | 0.070 |
Why?
|
| History, 19th Century | 1 | 2006 | 42 | 0.070 |
Why?
|
| Pulmonary Wedge Pressure | 2 | 2017 | 24 | 0.070 |
Why?
|
| Surface Properties | 1 | 2007 | 271 | 0.060 |
Why?
|
| School Health Services | 1 | 2007 | 62 | 0.060 |
Why?
|
| Cervical Vertebrae | 1 | 2007 | 100 | 0.060 |
Why?
|
| Cell Membrane | 1 | 2008 | 492 | 0.060 |
Why?
|
| Models, Economic | 1 | 2005 | 42 | 0.060 |
Why?
|
| Ehlers-Danlos Syndrome | 1 | 2005 | 5 | 0.060 |
Why?
|
| Streptomycin | 1 | 2005 | 12 | 0.060 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2005 | 25 | 0.060 |
Why?
|
| Jurisprudence | 1 | 2005 | 23 | 0.060 |
Why?
|
| Antiporters | 1 | 2005 | 7 | 0.060 |
Why?
|
| Maryland | 1 | 2005 | 32 | 0.060 |
Why?
|
| Atrial Premature Complexes | 1 | 2005 | 13 | 0.060 |
Why?
|
| Cardiology Service, Hospital | 1 | 2005 | 16 | 0.060 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2025 | 20 | 0.060 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2025 | 21 | 0.060 |
Why?
|
| Treatment Failure | 1 | 2005 | 188 | 0.060 |
Why?
|
| Decision Trees | 1 | 2004 | 51 | 0.060 |
Why?
|
| Multienzyme Complexes | 1 | 2005 | 77 | 0.060 |
Why?
|
| Septal Occluder Device | 1 | 2024 | 11 | 0.060 |
Why?
|
| Bundle-Branch Block | 1 | 2024 | 14 | 0.060 |
Why?
|
| Chordae Tendineae | 1 | 2004 | 1 | 0.060 |
Why?
|
| Hong Kong | 1 | 2004 | 3 | 0.060 |
Why?
|
| Lipids | 1 | 2006 | 306 | 0.060 |
Why?
|
| Verapamil | 1 | 2003 | 7 | 0.060 |
Why?
|
| Administration, Oral | 1 | 2005 | 344 | 0.060 |
Why?
|
| Midwestern United States | 1 | 2003 | 23 | 0.060 |
Why?
|
| Iatrogenic Disease | 1 | 2024 | 57 | 0.060 |
Why?
|
| Japan | 1 | 2003 | 57 | 0.060 |
Why?
|
| Actuarial Analysis | 1 | 2003 | 16 | 0.060 |
Why?
|
| Clinical Protocols | 1 | 2004 | 134 | 0.060 |
Why?
|
| Rupture | 1 | 2003 | 23 | 0.060 |
Why?
|
| Propensity Score | 1 | 2024 | 134 | 0.060 |
Why?
|
| Health Care Costs | 1 | 2005 | 204 | 0.050 |
Why?
|
| Heart Murmurs | 1 | 2003 | 3 | 0.050 |
Why?
|
| Length of Stay | 1 | 2007 | 771 | 0.050 |
Why?
|
| Antigens, CD | 1 | 2005 | 344 | 0.050 |
Why?
|
| Professional Competence | 1 | 2004 | 89 | 0.050 |
Why?
|
| Blood Flow Velocity | 1 | 2003 | 70 | 0.050 |
Why?
|
| False Positive Reactions | 1 | 2003 | 74 | 0.050 |
Why?
|
| Population Surveillance | 1 | 2004 | 205 | 0.050 |
Why?
|
| Carotid Artery, Internal | 1 | 2003 | 66 | 0.050 |
Why?
|
| Prealbumin | 1 | 2022 | 20 | 0.050 |
Why?
|
| Propafenone | 1 | 2002 | 1 | 0.050 |
Why?
|
| Enalapril | 1 | 2002 | 2 | 0.050 |
Why?
|
| Dogs | 1 | 2004 | 317 | 0.050 |
Why?
|
| Compartment Syndromes | 1 | 2002 | 10 | 0.050 |
Why?
|
| Rhabdomyolysis | 1 | 2002 | 26 | 0.050 |
Why?
|
| Patient Compliance | 1 | 2005 | 372 | 0.050 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2003 | 91 | 0.050 |
Why?
|
| Quality Indicators, Health Care | 1 | 2005 | 328 | 0.050 |
Why?
|
| Communication | 1 | 2007 | 554 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2003 | 436 | 0.050 |
Why?
|
| Marriage | 1 | 2002 | 25 | 0.050 |
Why?
|
| Life Style | 1 | 2004 | 328 | 0.050 |
Why?
|
| Mitral Valve Annuloplasty | 1 | 2021 | 18 | 0.050 |
Why?
|
| Heart Failure, Systolic | 1 | 2021 | 16 | 0.050 |
Why?
|
| Cell Communication | 1 | 2022 | 129 | 0.050 |
Why?
|
| Ontario | 1 | 2021 | 43 | 0.050 |
Why?
|
| Embolism | 1 | 2002 | 38 | 0.050 |
Why?
|
| Endophenotypes | 1 | 2021 | 8 | 0.050 |
Why?
|
| Extracellular Matrix | 1 | 2022 | 130 | 0.050 |
Why?
|
| Warfarin | 1 | 2002 | 109 | 0.050 |
Why?
|
| Protein Interaction Maps | 1 | 2021 | 33 | 0.050 |
Why?
|
| Ligands | 1 | 2022 | 422 | 0.040 |
Why?
|
| Heredity | 1 | 2020 | 7 | 0.040 |
Why?
|
| Penetrance | 1 | 2020 | 11 | 0.040 |
Why?
|
| Organ Size | 1 | 2020 | 161 | 0.040 |
Why?
|
| Blood Pressure | 2 | 2017 | 522 | 0.040 |
Why?
|
| Autophagy | 1 | 2021 | 205 | 0.040 |
Why?
|
| Random Allocation | 3 | 2005 | 199 | 0.040 |
Why?
|
| Glomerular Filtration Rate | 1 | 2019 | 96 | 0.040 |
Why?
|
| Body Size | 1 | 2018 | 23 | 0.040 |
Why?
|
| Thorax | 1 | 2018 | 34 | 0.040 |
Why?
|
| Surveys and Questionnaires | 1 | 2006 | 2592 | 0.040 |
Why?
|
| Procollagen | 1 | 2018 | 10 | 0.040 |
Why?
|
| Collagen Type I | 1 | 2018 | 39 | 0.040 |
Why?
|
| Calcium | 1 | 2021 | 555 | 0.040 |
Why?
|
| Transcriptome | 1 | 2021 | 326 | 0.040 |
Why?
|
| Necrosis | 1 | 2018 | 138 | 0.040 |
Why?
|
| Late Onset Disorders | 1 | 2017 | 3 | 0.040 |
Why?
|
| Vascular Resistance | 1 | 2017 | 44 | 0.040 |
Why?
|
| Oxygen Consumption | 1 | 2017 | 202 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2017 | 118 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2018 | 353 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2018 | 680 | 0.030 |
Why?
|
| Death Certificates | 1 | 2016 | 9 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 180 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2019 | 735 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2017 | 168 | 0.030 |
Why?
|
| Body Height | 1 | 2015 | 75 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2017 | 265 | 0.030 |
Why?
|
| Greece | 1 | 2014 | 3 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2014 | 133 | 0.030 |
Why?
|
| Haplotypes | 1 | 2014 | 116 | 0.030 |
Why?
|
| Time | 2 | 2005 | 27 | 0.030 |
Why?
|
| Drug Resistance | 1 | 2014 | 97 | 0.030 |
Why?
|
| Internationality | 1 | 2013 | 42 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2013 | 73 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 2012 | 40 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2021 | 2891 | 0.020 |
Why?
|
| Ventricular Myosins | 1 | 2009 | 6 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2009 | 116 | 0.020 |
Why?
|
| Tropomyosin | 1 | 2009 | 35 | 0.020 |
Why?
|
| Ion Channels | 1 | 2009 | 87 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2013 | 886 | 0.020 |
Why?
|
| Brain | 1 | 2017 | 1489 | 0.020 |
Why?
|
| Baroreflex | 1 | 2008 | 18 | 0.020 |
Why?
|
| Equipment Safety | 1 | 2008 | 21 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2008 | 128 | 0.020 |
Why?
|
| Elastic Modulus | 1 | 2008 | 35 | 0.020 |
Why?
|
| Stress, Mechanical | 1 | 2008 | 111 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2011 | 636 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2008 | 98 | 0.020 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2008 | 56 | 0.020 |
Why?
|
| Hypertension | 1 | 2013 | 601 | 0.020 |
Why?
|
| Autonomic Nerve Block | 1 | 2006 | 3 | 0.020 |
Why?
|
| Nutrition Assessment | 1 | 2007 | 58 | 0.020 |
Why?
|
| Trauma Severity Indices | 1 | 2007 | 38 | 0.020 |
Why?
|
| Heart Block | 1 | 2006 | 23 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2013 | 674 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2008 | 454 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2008 | 773 | 0.020 |
Why?
|
| Schools | 1 | 2007 | 156 | 0.020 |
Why?
|
| Medical Records | 1 | 2005 | 138 | 0.020 |
Why?
|
| Muscle Proteins | 1 | 2005 | 109 | 0.020 |
Why?
|
| Glycogen | 1 | 2005 | 46 | 0.020 |
Why?
|
| Glycogen Storage Disease Type II | 1 | 2005 | 23 | 0.010 |
Why?
|
| Energy Metabolism | 1 | 2007 | 349 | 0.010 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2004 | 51 | 0.010 |
Why?
|
| Animals, Domestic | 1 | 2003 | 13 | 0.010 |
Why?
|
| Hardness | 1 | 2002 | 7 | 0.010 |
Why?
|
| Rome | 1 | 2002 | 2 | 0.010 |
Why?
|
| Cardiac Volume | 1 | 2002 | 7 | 0.010 |
Why?
|
| Models, Cardiovascular | 1 | 2003 | 76 | 0.010 |
Why?
|
| Physical Fitness | 1 | 2002 | 92 | 0.010 |
Why?
|
| Observer Variation | 1 | 2002 | 201 | 0.010 |
Why?
|
| Apoptosis | 1 | 2004 | 1039 | 0.010 |
Why?
|